Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.

Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL.

Breast Cancer Res. 2011 Nov 2;13(5):R85. doi: 10.1186/bcr2937.

2.

Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.

Baquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, Rimm DL.

Cancer. 2012 Oct 1;118(19):4660-9. doi: 10.1002/cncr.27453. Epub 2012 Feb 22.

3.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
4.

Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.

Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, Rouzier R, Andre F, Hortobagyi GN, Wolmark N, Symmans WF.

J Clin Oncol. 2009 Sep 10;27(26):4287-92. doi: 10.1200/JCO.2008.21.6887. Epub 2009 Aug 10.

5.

Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.

Won HS, Lee KE, Sung SH, Choi MY, Jo JY, Nam EM, Mun YC, Seong CM, Lee SN.

Tumori. 2014 Jan-Feb;100(1):80-6. doi: 10.1700/1430.15820.

6.

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A.

Breast Cancer Res Treat. 2014 Apr;144(2):331-41. doi: 10.1007/s10549-014-2855-4. Epub 2014 Feb 12.

PMID:
24519386
7.

Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.

Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L.

Clin Cancer Res. 2007 Apr 1;13(7):2061-7.

8.

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J.

J Clin Oncol. 2011 Apr 1;29(10):1252-60. doi: 10.1200/JCO.2010.28.0982. Epub 2011 Mar 7.

9.

Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.

von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C.

J Clin Oncol. 2011 Jun 1;29(16):2150-7. doi: 10.1200/JCO.2010.31.9079. Epub 2011 Apr 25.

10.

BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.

Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechère L, Reed JC.

Clin Cancer Res. 2010 Aug 1;16(15):3988-97. doi: 10.1158/1078-0432.CCR-10-0079. Epub 2010 Jun 24.

11.

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C.

J Clin Oncol. 2013 Mar 1;31(7):860-7. doi: 10.1200/JCO.2011.41.0902. Epub 2013 Jan 22.

12.

Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.

Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC, McKiernan JM, Cordon-Cardo C.

J Urol. 2011 Nov;186(5):2094-100. doi: 10.1016/j.juro.2011.06.051. Epub 2011 Sep 23.

PMID:
21944130
13.

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G.

Breast Cancer Res. 2009;11(5):R69. doi: 10.1186/bcr2363. Epub .

14.

Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.

Smoter M, Bodnar L, Grala B, Stec R, Zieniuk K, Kozlowski W, Szczylik C.

J Exp Clin Cancer Res. 2013 Apr 30;32:25. doi: 10.1186/1756-9966-32-25.

15.

Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.

Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL.

Jpn J Clin Oncol. 2010 Apr;40(4):286-93. doi: 10.1093/jjco/hyp184. Epub 2010 Jan 19.

16.

Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.

Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, Timotheadou E, Christodoulou C, Pectasides D, Gogas H, Wirtz RM, Makatsoris T, Bafaloukos D, Aravantinos G, Televantou D, Pavlidis N, Fountzilas G.

Clin Breast Cancer. 2012 Jun;12(3):183-93. doi: 10.1016/j.clbc.2012.03.006. Erratum in: Clin Breast Cancer. 2012 Oct;12(5):386.

PMID:
22607768
17.

Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.

Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H, Aravantinos G, Christodoulou C, Makatsoris T, Linardou H, Pectasides D, Pavlidis N, Economopoulos T, Fountzilas G.

Ann Oncol. 2012 Jun;23(6):1422-7. doi: 10.1093/annonc/mdr527. Epub 2011 Nov 4.

18.

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.

Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M.

Breast. 2007 Feb;16(1):86-93. Epub 2006 Sep 28.

PMID:
17010609
19.

SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.

Collie-Duguid ES, Sweeney K, Stewart KN, Miller ID, Smyth E, Heys SD.

Breast Cancer Res Treat. 2012 Apr;132(3):807-18. doi: 10.1007/s10549-011-1625-9. Epub 2011 Jun 22.

PMID:
21695460
20.

HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.

Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.

Breast Cancer Res Treat. 2008 Mar;108(2):183-90. Epub 2007 Apr 28.

PMID:
17468948
Items per page

Supplemental Content

Write to the Help Desk